VIOLIN Logo
VO Banner
Search: for Help
About
Introduction
Statistics
VIOLIN News
Your VIOLIN
Register or Login
Submission
Tutorial
Vaccine & Components
Vaxquery
Vaxgen
VBLAST
Protegen
VirmugenDB
DNAVaxDB
CanVaxKB
Vaxjo
Vaxvec
Vevax
Huvax
Vaccine Mechanisms
Vaximmutordb
Vaxism
Vaxar
Vaccine Literature
VO-SciMiner
Litesearch
Vaxmesh
Vaxlert
Vaccine Design
Vaxign
Community Efforts
Vaccine Ontology
ICoVax 2012
ICoVax 2013
Advisory Committee
Vaccine Society
Vaxperts
VaxPub
VaxCom
VaxLaw
VaxMedia
VaxMeet
VaxFund
VaxCareer
Data Exchange
V-Utilities
VIOLINML
Help & Documents
Publications
Documents
FAQs
Links
Acknowledgements
Disclaimer
Contact Us
UMMS Logo

Vaccine Detail

M. tuberculosis DNA vaccine DNAAg85A encoding a single immunogenic M.tb Ag
Vaccine Information
  • Vaccine Name: M. tuberculosis DNA vaccine DNAAg85A encoding a single immunogenic M.tb Ag
  • Target Pathogen: Mycobacterium tuberculosis
  • Target Disease: Tuberculosis
  • Vaccine Ontology ID: VO_0004364
  • Type: DNA vaccine
  • Status: Research
  • Host Species as Laboratory Animal Model: Mouse
  • FbpA (Ag85A) gene engineering:
    • Type: DNA vaccine construction
    • Description: Vector pcDNA3.1 expressed a single immunogenic M.tb Ag (Ag85A) (Wang et al., 2004).
    • Detailed Gene Information: Click Here.
  • DNA vaccine plasmid: pcDNA3.1 DNA vaccine plasmid
  • Immunization Route: intranasal immunization
Host Response

Mouse Response

  • Vaccine Immune Response Type: VO_0000286
  • Efficacy: Systemic priming with two repeated DNAAg85A injections and respiratory mucosal boosting once with AdAg85A provided the most potent protection of all of the tested vaccines/regimens, including s.c. BCG vaccination both at 4 and 8 wk postchallenge, and this level of protection was also better than single i.n. AdAg85A vaccination at 8 wk postchallenge (Wang et al., 2004).
  • Information about this animal model: Mouse Model for TB research
References
Wang et al., 2004: Wang J, Thorson L, Stokes RW, Santosuosso M, Huygen K, Zganiacz A, Hitt M, Xing Z. Single mucosal, but not parenteral, immunization with recombinant adenoviral-based vaccine provides potent protection from pulmonary tuberculosis. Journal of immunology (Baltimore, Md. : 1950). 2004; 173(10); 6357-6365. [PubMed: 15528375].